文献速递血管炎

儿童ANCA相关性血管炎的血浆置换治疗:多中心真实世界经验

Therapeutic plasma exchange in paediatric ANCA-associated vasculitis: a multicentre real-world experience.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

TPE组基线疾病活动度更高(中位PVAS 12 vs 7,P=0.004)且肾脏受累更重,TPE与PVAS显著下降相关(中位12.0降至4.5,P=0.007),但严重基线肾病患者持续肾脏异常仍常见。

要点

  • TPE在儿童AAV中选择性用于重症或难治性患者,尤其晚期肾脏受累者。
  • TPE组基线PVAS更高(中位12 vs 7,P=0.004)且肾脏受累更严重。
  • TPE后PVAS显著下降(中位12.0降至4.5,P=0.007),但严重肾病者持续异常常见。

核心结论

  • TPE在儿童AAV中作为重症或难治性患者的辅助治疗选择性使用,尤其适用于晚期肾脏受累者。
  • TPE后疾病活动度和急性器官威胁表现改善,但严重基线肾病患者持续肾脏异常仍常见。

研究设计与样本

  • 患者分为TPE治疗组(TPE+,11例,42.3%)和非TPE治疗组(TPE-),比较人口学、器官受累、实验室指标、PVAS、治疗、不良事件和结局。

主要发现

  • TPE+组诊断时疾病活动度显著更高(中位PVAS 12 vs 7,P=0.004),肾脏受累更严重,血清肌酐更高、估算肾小球滤过率更低。
  • 严重肺部、胃肠道、心血管和皮肤表现主要见于TPE+组。
  • TPE的主要指征为严重肾脏受累。
  • TPE与PVAS显著下降相关(中位12.0降至4.5,P=0.007)。
  • 大多数急性器官威胁表现临床改善,但严重基线肾脏受累者持续异常常见;1例患者在治疗期间死于导管相关铜绿假单胞菌脓毒症。

关键数值与推荐

  • AAV诊断依据EULAR/PRINTO/PRES标准。
  • TPE+组基线中位PVAS 12 vs TPE-组7(P=0.004)。
  • TPE后PVAS中位从12.0降至4.5(P=0.007)。

临床怎么用

  • 对儿童AAV伴严重肾脏受累或重症/难治性表现者可考虑TPE作为辅助治疗。
  • TPE后需关注严重基线肾病患者持续肾脏异常的可能。
  • TPE治疗期间需警惕导管相关感染等不良事件。

局限性

  • 非随机分组,TPE组基线疾病活动度和肾脏受累更重,存在选择偏倚。
  • 原文未报告长期随访结局及TPE对终末期肾病等硬终点的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is a rare but potentially life-threatening condition in children, often presenting with severe multi-organ involvement. Although standard induction therapy includes cyclophosphamide or rituximab with glucocorticoids, the role of therapeutic plasma exchange (TPE) in paediatric AAV remains uncertain. This study sought to describe the clinical characteristics, indications and outcomes of paediatric AAV patients treated with TPE in real-world practice and to compare them with patients managed without TPE. METHODS: This retrospective multicentre study included children (<18 years) diagnosed with AAV according to EULAR/PRINTO/PRES criteria. Patients were classified into TPE-treated (TPE+) and non-TPE-treated (TPE-) groups. Demographic features, organ involvement, laboratory parameters, Paediatric Vasculitis Activity Score (PVAS), treatments, adverse events and outcomes were analysed. RESULTS: Twenty-six paediatric AAV patients were included, of whom 11 (42.3%) underwent TPE. At diagnosis, the TPE+ group had significantly higher disease activity (median PVAS 12 vs 7, P = 0.004) and more severe kidney involvement, with higher serum creatinine and lower estimated glomerular filtration rate. Severe pulmonary, gastrointestinal, cardiovascular and cutaneous manifestations occurred predominantly in the TPE+ group. The primary indication for TPE was severe kidney involvement. TPE was associated with a significant reduction in PVAS (median 12.0-4.5, P = 0.007). Clinical improvement was observed in most acute organ-threatening manifestations, although persistent abnormalities remained common among patients with severe baseline kidney involvement. One patient died from catheter-related Pseudomonas aeruginosa sepsis during treatment. CONCLUSION: TPE is selectively used as an adjunctive therapy in children with severe or refractory AAV, particularly in those with advanced kidney involvement. Although disease activity and acute organ-threatening manifestations improved following TPE, persistent renal abnormalities remained frequent, reflecting the severity of baseline kidney disease.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Menentoğlu B, Küçükali B, Demirkan FG, et al. Therapeutic plasma exchange in paediatric ANCA-associated vasculitis: a multicentre real-world experience. Rheumatology (Oxford). 2026. PMID: 42714965. doi:10.1093/rheumatology/keag497

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。